Had Metrics been professionally managed they
would have been developing similar products to
the type we now further dilute and add to debt of
Mayne. It appears in USA we are purely a marketing
company of pharmaceutical products and not a
core pharmaceutical company as such. With unique
exclusive medication which is in high demand, should
it be really groundbreaking sales staff is the last thing
you need. The product should it be best in field will
soon take market share.
Ann: MYX signs license agreement for women's health products, page-31
-
- There are more pages in this discussion • 167 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MYX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.40 |
Change
0.140(3.29%) |
Mkt cap ! $374.3M | |||
| Open | High | Low | Value | Volume |
| $4.25 | $4.43 | $4.25 | $618.9K | 141.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 2957 | $4.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.41 | 968 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MYX (ASX) Chart |